Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Based on systematic druggable genome-wide Mendelian randomization identifies therapeutic targets for diabetes.

Frontiers in endocrinology - 1 Jan 2024

Li Hu, Li Wei, Li Dongyang, Yuan Lijuan, Xu Yucheng, Su Pengtao, Wu Liqiang, Zhang Zhiqiang

Abstract excerpt

Purpose: Diabetes and its complications cause a heavy burden of disease worldwide. In recent years, Mendelian randomization (MR) has been widely used to discover the pathogenesis and epidemiology of diseases, as well as to discover new therapeutic targets. Therefore, based on systematic "druggable" genomics, we aim to identify new therapeutic targets for diabetes and analyze its pathophysiological mechanisms to...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Bayes Theorem
Share to Diabetes Mellitus, Type 1

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Diabetes Mellitus, Type 2

Share to Genome-Wide Association Study

Share to Genomics

Share to Hypoglycemic Agents

Share to Mendelian Randomization Analysis

Share to Quantitative Trait Loci

Source

Open in PubMed Open full text

Identifiers

PMID: 38915894
DOI: 10.3389/fendo.2024.1366290
PMCID: PMC11194396

Genes

C4B
ATP2A1
CCNE2
CD69
ERBB3
IL27
KCNJ11
KIF11
MAP3K13
NRBP1
PEAK1
PTPN22
REG4

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Based on systematic druggable genome-wide Mendelian randomization identifies therapeutic targets for diabetes.PMID 38915894Read ↗

Comprehensive Druggable Genome-Wide Mendelian Randomization Reveals Therapeutic Targets for Kidney DiseasesSemantic proximity Read ↗

Transcriptome analysis combined with Mendelian randomization screening for biomarkers causally associated with diabetic retinopathySemantic proximity Read ↗

Potential Drug Targets for Diabetic Retinopathy Identified Through Mendelian Randomization Analysis.Semantic proximity Read ↗

Causal Evaluation of Laboratory Markers in Type 2 Diabetes on Cancer and Vascular Diseases Using Various Mendelian Randomization ToolsSemantic proximity Read ↗

Genetic evidence for efficacy of targeting IL-2, IL-6, and TYK2 signaling in prevention of type 1 diabetes: A Mendelian randomization studySemantic proximity Read ↗

A genetically supported drug repurposing pipeline for diabetes treatment using electronic health recordsSemantic proximity Read ↗

Genetically proxied therapeutic inhibition of kidney function drug targets and type 2 diabetes in Africans: A Mendelian randomization studySemantic proximity Read ↗

Causal association evaluation of diabetes with Alzheimer's disease and genetic analysis of antidiabetic drugs against Alzheimer's diseaseSemantic proximity Read ↗

Transcriptome-wide Mendelian randomization during CD4+ T cell activation reveals immune-related drug targets for cardiometabolic diseases.Semantic proximity Read ↗

Genetic insights into therapeutic targets for gout: evidence from a multi-omics mendelian randomization study.Semantic proximity Read ↗

Precision Medicine in Patients with Differential Diabetic Phenotypes: Novel Opportunities from Network Medicine.Semantic proximity Read ↗

Pharmacogenetics of type 2 diabetes mellitus, the route toward tailored medicineSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.